Ubs Oconnor LLC Scynexis Inc Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Scynexis Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 160,160 shares of SCYX stock, worth $201,801. This represents 0.02% of its overall portfolio holdings.

Number of Shares

160,160

Holding current value

$201,801

% of portfolio

0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.27 - $2.23 $18,893 - $33,175	14,877 Added 10.24%	160,160 $238,000
Q2 2024 Aug 14, 2024	BUY	$1.4 - $2.77 $4,972 - $9,839	3,552 Added 2.51%	145,283 $290,000
Q1 2024 May 15, 2024	SELL	$1.39 - $2.21 $66,353 - $105,496	-47,736 Reduced 25.19%	141,731 $208,000
Q4 2023 Feb 14, 2024	SELL	$1.56 - $2.24 $275,421 - $395,476	-176,552 Reduced 48.24%	189,467 $422,000
Q3 2023 Nov 14, 2023	SELL	$1.93 - $3.64 $38,600 - $72,800	-20,000 Reduced 5.18%	366,019 $834,000
Q2 2023 Aug 14, 2023	BUY	$2.38 - $3.67 $918,725 - $1.42 Million	386,019 New	386,019 $1.14 Billion
Q1 2023 May 15, 2023	BUY	$1.15 - $3.0 $57,499 - $150,000	50,000 Added 9.33%	585,670 $1.76 Million
Q3 2022 Nov 14, 2022	BUY	$1.83 - $2.93 $53,853 - $86,224	29,428 Added 5.81%	535,670 $1.29 Billion
Q2 2022 Aug 12, 2022	BUY	$1.77 - $3.87 $896,048 - $1.96 Million	506,242 New	506,242 $941,000

Others Institutions Holding SCYX

# of Institutions

Shares Held

13.8M

Call Options Held

21.9K

Put Options Held

2.6K

Federated Hermes, Inc. Pittsburgh, PA

3.6M
Shares

$4.53 Million
0.01% of portfolio
Kingdon Capital Management, L.L.C. New York, NY

2.24M
Shares

$2.82 Million
0.4% of portfolio
Vanguard Group Inc Valley Forge, PA

1.69M
Shares

$2.13 Million
0.0% of portfolio
Avidity Partners Management LP Dallas, TX

1.45M
Shares

$1.83 Million
0.13% of portfolio
Amh Equity LTD

600K
Shares

$756,000
1.24% of portfolio

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $41.1M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account